2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Transitional Cell
29
Carcinoma, Non-Small-Cell Lung
29
Urinary Bladder Neoplasms
26
Neoplasms
22
Carcinoma, Renal Cell
22
Carcinoma, Merkel Cell
21
Neoplasm Metastasis
18
Colorectal Neoplasms
16
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
14
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
9
Melanoma
9
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Recurrence
6
Carcinoma, Hepatocellular
6
Ureteral Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Urethral Neoplasms
4
Sarcoma
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Carcinoma, Squamous Cell
4
Uterine Cervical Neoplasms
3
Turcot syndrome
3
Skin Neoplasms
3
Interventions
Cyclophosphamide
83
Peripheral Blood Stem Cell Transplantation
76
fludarabine phosphate
74
Busulfan
60
Cyclosporine
57
Imatinib Mesylate
50
Mycophenolic Acid
49
Antilymphocyte Serum
48
Tacrolimus
44
Radiotherapy
44
Filgrastim
43
Methotrexate
39
Whole-Body Irradiation
34
Dasatinib
34
Methylprednisolone
30
Cord Blood Stem Cell Transplantation
26
nilotinib
25
Melphalan
24
Cytarabine
23
Interferon-alpha
22
Etoposide
20
sargramostim
19
Flow Cytometry
13
Therapeutics
11
Cyclosporins
11
Sirolimus
10
Polymerase Chain Reaction
10
bosutinib
9
Thiotepa
9
Hydroxyurea
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Chronic-Phase
×
avelumab
×
Clear all
NCT02767063
2020-08-07
ACTIW
Versailles Hospital
Phase 1/2
Unknown
100 enrolled